

Acetylsalicylic acid

Section

Medicines for juvenile joint diseases
 Oral > Solid: 100 to 500 mg
 Local > Rectal > Suppository: 50 to 150 mg

Indications

Acute rheumatic fever without mention of heart involvement

Mucocutaneous lymph node syndrome

Juvenile idiopathic arthritis

Adalimumab

Section

Medicines for juvenile joint diseases
 Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL;
 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Juvenile idiopathic arthritis

Allopurinol

Section

Medicines used to treat gout
 Oral > Solid: 100 mg

Indications

Gout

Anakinra

Section

Medicines for juvenile joint diseases
 Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

Azathioprine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)
 Oral > Solid > tablet: 50 mg (scored)

Indications

Rheumatoid arthritis, serology unspecified

Psoriatic arthritis

Certolizumab pegol

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

Chloroquine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)

Indications

Rheumatoid arthritis

Colchicine

Section

Medicines used to treat gout

Oral > Solid: 0.5 mg

Indications

Gout

Etanercept

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

Golimumab

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

Hydroxychloroquine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 200 mg (as sulfate)

Indications

Systemic lupus erythematosus

Cutaneous lupus erythematosus of unspecified type

Infliximab

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

Methotrexate

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid > tablet: 2.5 mg (as sodium salt)

Medicines for juvenile joint diseases

Oral > Solid > tablet: 2.5 mg (as sodium salt)

Indications

Rheumatoid arthritis, serology unspecified

Juvenile idiopathic arthritis

Penicillamine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 250 mg

Indications

Rheumatoid arthritis, serology unspecified

Probenecid

Section

Medicines used to treat gout

Oral > Solid: 500 mg

Indications

Gout

Sulfasalazine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 500 mg

Indications

Rheumatoid arthritis, serology unspecified

Tocilizumab

Section

Medicines for juvenile joint diseases

Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial

Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

Triamcinolone hexacetonide

Section

Medicines for juvenile joint diseases

Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial

Indications

Juvenile idiopathic arthritis